CLINICAL_TRIALS
trial_result
· 2026-04-29
Clinical Trial Update: A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo [Phase 3]
Summary
A 52-week Phase 3 study evaluating the safety and effects of ritlecitinib in participants with nonsegmental vitiligo.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Vitiligo | Phase 3 | Status: ACTIVE_NOT_RECRUITING